📊 MAIA Key Takeaways
Is MAIA Biotechnology, Inc. (MAIA) a Good Investment?
MAIA is a pre-revenue biotech company in severe financial distress with zero cash reserves and negative operating cash burn of $5.3M. The combination of no revenue, depleted cash position, and mounting operating losses creates an existential liquidity crisis that requires immediate capital infusion or asset sales to remain viable.
MAIA Biotechnology shows the classic high-risk profile of a pre-revenue biotech, but with especially weak fundamentals at this stage: no revenue, large operating and net losses, and deeply negative cash generation. While the balance sheet carries no long-term debt, the combination of minimal equity, very poor returns on assets and equity, and apparent cash scarcity materially weakens financial resilience and increases dependence on external financing.
MAIA Biotechnology, Inc. Key Strengths (MAIA)
- No debt obligations limiting financial flexibility
- Positive stockholders' equity of $27.8M provides some asset base
- Recent insider activity suggests management engagement despite challenges
- No long-term debt reduces balance sheet leverage risk
- Current and quick ratios above 1.0 suggest near-term liabilities are still covered on paper
- EPS loss improved versus the prior year, indicating some per-share loss moderation
MAIA Stock Risks: MAIA Biotechnology, Inc. Investment Risks
- Critical cash position: $0.00 reported with negative quarterly burn of $5.3M threatens immediate solvency
- No revenue generation despite apparent commercial stage, indicating failed market adoption or development setback
- Negative ROE (-22.9%) and ROA (-18.0%) indicate shareholder value destruction and asset inefficiency
- Unsustainable cash burn rate: at current pace, company has minimal runway absent emergency financing
- No revenue base means the business has not yet demonstrated commercial viability
- Large operating and free cash flow losses imply ongoing cash burn and likely financing pressure
- Very low equity base and extremely negative ROE/ROA indicate fragile financial health
Key Metrics to Watch
- Cash position and runway to next financing milestone
- Quarterly cash burn trend and path to profitability
- Revenue generation from any clinical or commercial pipeline advancement
- Quarterly cash balance and operating cash burn
- Any transition from zero revenue to sustainable collaboration, licensing, or product revenue
MAIA Biotechnology, Inc. (MAIA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.59x current ratio provides a solid financial cushion.
MAIA Profit Margin, ROE & Profitability Analysis
MAIA vs Healthcare Sector: How MAIA Biotechnology, Inc. Compares
How MAIA Biotechnology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MAIA Biotechnology, Inc. Stock Overvalued? MAIA Valuation Analysis 2026
Based on fundamental analysis, MAIA Biotechnology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MAIA Biotechnology, Inc. Balance Sheet: MAIA Debt, Cash & Liquidity
MAIA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: MAIA Biotechnology, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.05 indicates the company is currently unprofitable.
MAIA Revenue Growth, EPS Growth & YoY Performance
MAIA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2022 | N/A | -$1.5M | $-0.49 |
| Q2 2022 | N/A | -$1.0M | $-0.40 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MAIA Biotechnology, Inc. Dividends, Buybacks & Capital Allocation
MAIA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for MAIA Biotechnology, Inc. (CIK: 0001878313)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MAIA
What is the AI rating for MAIA?
MAIA Biotechnology, Inc. (MAIA) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MAIA's key strengths?
Claude: No debt obligations limiting financial flexibility. Positive stockholders' equity of $27.8M provides some asset base. ChatGPT: No long-term debt reduces balance sheet leverage risk. Current and quick ratios above 1.0 suggest near-term liabilities are still covered on paper.
What are the risks of investing in MAIA?
Claude: Critical cash position: $0.00 reported with negative quarterly burn of $5.3M threatens immediate solvency. No revenue generation despite apparent commercial stage, indicating failed market adoption or development setback. ChatGPT: No revenue base means the business has not yet demonstrated commercial viability. Large operating and free cash flow losses imply ongoing cash burn and likely financing pressure.
What is MAIA's revenue and growth?
MAIA Biotechnology, Inc. reported revenue of $0.0.
Does MAIA pay dividends?
MAIA Biotechnology, Inc. does not currently pay dividends.
Where can I find MAIA SEC filings?
Official SEC filings for MAIA Biotechnology, Inc. (CIK: 0001878313) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MAIA's EPS?
MAIA Biotechnology, Inc. has a diluted EPS of $-0.14.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is MAIA's fundamental grade?
Based on our AI fundamental analysis in June 2026, MAIA Biotechnology, Inc. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is MAIA stock overvalued or undervalued?
Valuation metrics for MAIA: ROE of -22.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is MAIA's AI grade for 2026?
Our dual AI analysis gives MAIA Biotechnology, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MAIA's free cash flow?
MAIA Biotechnology, Inc.'s operating cash flow is $-5.3M, with capital expenditures of N/A.
How does MAIA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -22.9% (avg: 15%), current ratio 5.59 (avg: 2).